skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors

Review

(3569) Views  (2675) Full article downloads

Authors: Alberto F Rubio-Guerra, David Castro-Serna, Cesar I Elizalde Barrera, et al

Published Date November 2009 Volume 2009:2 Pages 55 - 62
DOI: http://dx.doi.org/10.2147/IBPC.S6232

Alberto F Rubio-Guerra1, David Castro-Serna2, Cesar I Elizalde Barrera2, Luz M Ramos-Brizuela2

1Metabolic and Research Clinic, 2Internal Medicine Department, Hospital General de Ticomán SS DF, México

Abstract: Recent guidelines for the management of hypertension recommend target blood pressures <140/90 mmHg in hypertensive patients, or <130/80 mmHg in subjects with diabetes, chronic kidney disease, or coronary artery disease. Despite the availability and efficacy of antihypertensive drugs, most hypertensive patients do not reach the recommended treatment targets with monotherapy, making combination therapy necessary to achieve the therapeutic goal. Combination therapy with 2 or more agents is the most effective method for achieving strict blood pressure goals. Fixed-dose combination simplifies treatment, reduces costs, and improves adherence. There are many drug choices for combination therapy, but few data are available about the efficacy and safety of some specific combinations. Combination therapy of calcium antagonists and inhibitors of the renin-angiotensin-aldosterone system (RAAS) are efficacious and safe, and have been considered rational by both the JNC 7 and the 2007 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. The aim of this review is to discuss some relevant issues about the use of combinations with calcium channel blockers and RAAS inhibitors in the treatment of hypertension.

Keywords: hypertension, calcium channel blockers, renin-angiotensin-aldosterone system inhibitors, fixed-dose combination, adherence






 

Other articles by Dr Alberto Rubio-Guerra



Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
Clinical approach in treatment of resistant hypertension
Comparative assessment of angiotensin receptor blockers in different clinical settings
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction
Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness
Is tetrahydrobiopterin a therapeutic option in diabetic hypertensive patients?
Long-term use and tolerability of irbesartan for control of hypertension
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University